Gastrointestinal Stromal Tumors Diagnosis and Treatment

1
Gastrointestinal Stromal Tumor (GIST) - Pipeline
Review H1 2016
Telephone [phone]Mail at
sales_at_researchbeam.com
(Type, Mode of action, Crop Type and Geography) -
Size, Share, Global Trends, Company Profiles,
Demand, Insights, Analysis, Research, Report,
Opportunities, Segmentation and Forecast, 2013 -
2020
Published on Oct 2014
2


Report Overview

• Gastrointestinal Stromal Tumor (GIST) - Pipeline
  Review, H1 2016, provides an overview of the
  Gastrointestinal Stromal Tumor (GIST) pipeline
  landscape.
• The report provides comprehensive information on
  the therapeutics under development for
  Gastrointestinal Stromal Tumor (GIST), complete
  with analysis by stage of development, drug
  target, mechanism of action (MoA), route of
  administration (RoA) and molecule type. The
  report also covers the descriptive
  pharmacological action of the therapeutics, its
  complete research and development history and
  latest news and press releases. Additionally, the
  report provides an overview of key players
  involved in therapeutic development for
  Gastrointestinal Stromal Tumor (GIST) and
  features dormant and discontinued projects.
• Global Markets Directs report features
  investigational drugs from across globe covering
  over 20 therapy areas and nearly 3,000
  indications. The report is built using data and
  information sourced from Global Markets Directs
  proprietary databases, company/university
  websites, clinical trial registries, conferences,
  SEC filings, investor presentations and featured
  press releases from company/university sites and
  industry-specific third party sources. Drug
  profiles featured in the report undergoes
  periodic review following a stringent set of
  processes to ensure that all the profiles are
  updated with the latest set of information.
  Additionally, various dynamic tracking processes
  ensure that the most recent developments are
  captured on a real time basis.
• The report helps in identifying and tracking
  emerging players in the market and their
  portfolios, enhances decision making capabilities
  and helps to create effective counter strategies
  to gain competitive advantage.
• Strategic Focus Report _at_ http//www.researchbeam.c
  om/gastrointestinal-stromal-tumor-gist-pipeline-re
  view-h1-2016-market

3


Report Overview

• Scope
• - The report provides a snapshot of the global
  therapeutic landscape of Gastrointestinal Stromal
  Tumor (GIST)
• - The report reviews pipeline therapeutics for
  Gastrointestinal Stromal Tumor (GIST) by
  companies and universities/research institutes
  based on information derived from company and
  industry-specific sources
• - The report covers pipeline products based on
  various stages of development ranging from
  pre-registration till discovery and undisclosed
  stages
• The report assesses Gastrointestinal Stromal
  Tumor (GIST) therapeutics based on drug target,
  mechanism of action (MoA), route of
  administration (RoA) and molecule type
• Reasons to buy
• - Gain strategically significant competitor
  information, analysis, and insights to formulate
  effective RD strategies
• - Identify emerging players with potentially
  strong product portfolio and create effective
  counter-strategies to gain competitive advantage
• - Identify and understand important and diverse
  types of therapeutics under development for
  Gastrointestinal Stromal Tumor (GIST)
• - Devise corrective measures for pipeline
  projects by understanding Gastrointestinal
  Stromal Tumor (GIST) pipeline depth and focus of
  Indication therapeutics

4


Table of Contents
Table of Contents 2 List of Tables 7 List of
Figures 8 Introduction 9 Global Markets Direct
Report Coverage 9 Gastrointestinal Stromal Tumor
(GIST) Overview 10 Therapeutics Development
11 Pipeline Products for Gastrointestinal Stromal
Tumor (GIST) - Overview 11 Pipeline Products for
Gastrointestinal Stromal Tumor (GIST) -
Comparative Analysis 12 Gastrointestinal Stromal
Tumor (GIST) - Therapeutics under Development by
Companies 13 Gastrointestinal Stromal Tumor
(GIST) - Therapeutics under Investigation by
Universities/Institutes 15 Gastrointestinal
Stromal Tumor (GIST) - Pipeline Products Glance
16 Late Stage Products 16 Clinical Stage Products
17 Early Stage Products 18 Gastrointestinal
Stromal Tumor (GIST) - Products under Development
by Companies 19 Gastrointestinal Stromal Tumor
(GIST) - Products under Investigation by
Universities/Institutes 21 Gastrointestinal
Stromal Tumor (GIST) - Companies Involved in
Therapeutics Development 22 Advenchen
Laboratories, LLC 23 Ariad Pharmaceuticals, Inc.
24 Arog Pharmaceuticals, Inc. 25 Array BioPharma
Inc. 26 Astex Pharmaceuticals, Inc. 27
5


Table of Contents
Blueprint Medicines Corporation 28 Boston
Biomedical, Inc. 29 Calithera Biosciences, Inc.
30 Chipscreen Biosciences Ltd 31 Deciphera
Pharmaceuticals, LLC 32 F. Hoffmann-La Roche Ltd.
33 Horizon Pharma Plc 34 Immunicum AB 35 Jiangsu
Hengrui Medicine Co., Ltd. 36 Kolltan
Pharmaceuticals, Inc. 37 Natco Pharma Limited
38 Nerviano Medical Sciences S.r.l. 39 Novartis
AG 40 Omeros Corporation 41 Plexxikon Inc. 42 TG
Therapeutics, Inc. 43 Threshold Pharmaceuticals,
Inc. 44 Gastrointestinal Stromal Tumor (GIST) -
Therapeutics Assessment 45 Assessment by
Monotherapy Products 45 Assessment by Combination
Products 46 Assessment by Target 47 Assessment by
Mechanism of Action 50 Assessment by Route of
Administration 53
6


Report Ordering
Report Name Gastrointestinal
Stromal Tumor GIST - Pipeline Review H1
2016
Product Price
User Price
Single User US 1700
Site User US 4000
Global User US 6000
To View Sample or Purchase Report
7



Contact Us
FOR MORE DETAILS
Visit us at
http//www.researchbeam.com/gastrointestinal-strom
al-tumor-gist-pipeline-review-h1-2016-market
Stay With Us At
5933 NE Win Sivers Drive,205, Portland, OR
97220United States
TELEPHONE [phone] DIRECT 1 (503)
894-6022E-MAIL sales_at_researchbeam.com